From Single Agents to Synergy: Redefining Therapeutic Strategies in MASLD
- 1First Department of Internal Medicine, General Hospital Laiko, Medical School, National and Kapodistrian University of Athens, AgiouThoma 17, 11527 Athens, Greece
Abstract
The recent approvals of resmetirom and semaglutide have marked a pivotal advance in the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Nevertheless, the modest fibrosis responses observed with current monotherapies and the persistence of substantial residual disease burden highlight the need for more comprehensive therapeutic strategies. Given the multifactorial pathogenesis of MASLD, combination therapy has emerged as a promising approach to simultaneously target metabolic dysfunction, hepatic steatosis, inflammation, and fibrogenesis. In this opinion article, we discuss the biological rationale for combination treatment and critically appraise the evidence from randomized clinical trials evaluating multidrug approaches in MASLD. While several studies have demonstrated encouraging improvements in hepatic and metabolic outcomes, others have failed to achieve their primary endpoints, underscoring that mechanistic complementarity does not necessarily translate into clinical synergy. We further review ongoing trials, including studies in advanced fibrosis and compensated cirrhosis, that are expected to shape the next phase of therapeutic development. Finally, we address key challenges related to patient selection, disease heterogeneity, treatment duration, safety, cost-effectiveness, and regulatory approval. We propose that the future of combination therapy in MASLD will likely rely on precision-medicine approaches that align therapeutic mechanisms with individual disease biology and stage.
Related
- Editorial: Redefining acute psychiatric care: strategies for improved inpatient experiences, vol II
- Redefining drug discovery: AI-driven strategies for efficient cancer therapeutics.
- Establishing an in Vitro Model of Astrocyte Activation in Ischemic Traumatic Brain Injury: Therapeutic Synergy of Melatonin and Oxygen Nanobubbles
- Redefining Gynecomastia Grading Using Anthropometric Parameters and Surgical Algorithm for Gynecomastia: A Single-center Study.
- Curcuminoids and Dimethoxycurcumin as Therapeutic Agents in Melanoma: Focus on Metastasis and Primary Care Integration.
BibTeX
@article{chrysavgis2026from,
title = {{From Single Agents to Synergy: Redefining Therapeutic Strategies in MASLD}},
author = {Lampros Chrysavgis and Evangelos Cholongitas},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = sep,
doi = {10.3390/ijms27188368},
url = {https://www.mdpi.com/1422-0067/27/18/8368},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - From Single Agents to Synergy: Redefining Therapeutic Strategies in MASLD
AU - Lampros Chrysavgis
AU - Evangelos Cholongitas
PY - 2026
DA - 2026/09/20
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27188368
UR - https://www.mdpi.com/1422-0067/27/18/8368
AB - The recent approvals of resmetirom and semaglutide have marked a pivotal advance in the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Nevertheless, the modest fibrosis responses observed with current monotherapies and the persistence of substantial residual disease burden highlight the need for more comprehensive therapeutic strategies. Given the multifactorial pathogenesis of MASLD, combination therapy has emerged as a promising approach to simultaneously target metabolic dysfunction, hepatic steatosis, inflammation, and fibrogenesis. In this opinion article, we discuss the biological rationale for combination treatment and critically appraise the evidence from randomized clinical trials evaluating multidrug approaches in MASLD. While several studies have demonstrated encouraging improvements in hepatic and metabolic outcomes, others have failed to achieve their primary endpoints, underscoring that mechanistic complementarity does not necessarily translate into clinical synergy. We further review ongoing trials, including studies in advanced fibrosis and compensated cirrhosis, that are expected to shape the next phase of therapeutic development. Finally, we address key challenges related to patient selection, disease heterogeneity, treatment duration, safety, cost-effectiveness, and regulatory approval. We propose that the future of combination therapy in MASLD will likely rely on precision-medicine approaches that align therapeutic mechanisms with individual disease biology and stage.
SN - 1422-0067
ER -